The Kingdom of Bahrain will be the first Arab country taking part in the solidarity test as part of the ongoing efforts at all levels to contain and prevent the spread of the Coronavirus.
The World Health Organization (WHO) has begun testing its first anti-coronavirus drug, produced 60 days after the genetic sequence of the Coronavirus (COVID-19) was shared by China, under the “Solidarity Trial” experiment.
Bahrain, Argentina, Canada, France, Iran, Norway, South Africa, Switzerland, Thailand, and Spain, will all participate in the trial, aimed at jumpstarting research for the establishment of a treatment designed to eradicate COVID-19.
The experimental treatments will be evaluated and compared to established health treatment protocols for each country alongside robust data showing which treatments are most effective in combating the virus.
In a press conference held in Cairo by the WHO Regional Office for the Eastern Mediterranean, the Kingdom was commended for its wide-ranging efforts in containing the spread of the COVID-19, which include the introduction of the contact tracing method, a rapid response measure used to trace the contacts of active COVID-19 cases, as well as the provision of fully equipped isolation wards for the treatment of active cases, under a specialised medical team. The Kingdom was further commended for its persistence in following the health guidelines issued by the WHO.
The Kingdom’s ongoing preventative efforts have been previously recognised by the World Health Organization’s (WHO) Regional Office for the Eastern Mediterranean, for the “overall comprehensive approach” followed in combatting the spread of the virus and safeguarding the health and safety of citizens and residents.